Abstract
The peripheral benzodiazepine receptor (PBR) has been shown to play a key role in the regulation of the mitochondrial process leading to apoptosis. Despite much controversy in the literature on this subject, PBR synthetic ligands (and specifically agonists such as Ro5-4864 and SSR180575) are described as presenting potent anti-apoptotic effect against oxidative stress, TNFalpha- and tamoxifen-induced apoptosis when the PBR ligand is administrated at a low dose, close to the affinity range of the ligand to its receptor. Such anti-apoptotic activity has already been correlated with a protective effect of PBR ligands against ischemia-reperfusion induced tissue dysfunction. Previously, we had shown that SSR180575 is a specific and high affinity PBR ligand of potential interest in pathological cardiovascular, renal and neurodegenerative indications. Beyond its expression in steroid-producing tissues, heart, liver and kidney, the PBR is also known to be highly expressed in blood cells. In this work, we demonstrate by flow cytometry experiments, that SSR180575, at low concentrations, is able to protect polymorphonuclear leukocytes (PMNs) against TNFalpha-induced apoptosis in whole blood. Thus, in a new context, SSR180575 again shows p...Continue Reading
References
Oct 20, 1977·Nature·C BraestrupR F Squires
May 1, 1992·Journal of Neurochemistry·M GavishR Weizman
Apr 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M W McEneryS H Snyder
Dec 1, 1985·Journal of Neurochemistry·P J SyapinE P Noble
Apr 18, 1983·Life Sciences·G Le FurC Guérémy
Aug 1, 1983·Life Sciences·G Le FurA Uzan
Sep 13, 1993·FEBS Letters·I Szabó, M Zoratti
Jan 1, 1993·Life Sciences·X CanatP Casellas
Jan 1, 1997·AIDS·A CossarizzaC Franceschi
Jan 27, 1998·The Journal of Biological Chemistry·E Joseph-LiauzunP Ferrara
Nov 24, 1999·Biochemical and Biophysical Research Communications·F BonoJ M Herbert
Mar 27, 2001·Biochemical Pharmacology·B ChelliC Martini
Oct 3, 2001·Journal of Neurovirology·J R LokensgardP K Peterson
Dec 6, 2001·Leukemia Research·Deborah E BankerFinbarr E Cotter
Dec 18, 2001·British Journal of Cancer·K MaaserH Scherübl
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Badia FerzazBernard Scatton
Jul 11, 2002·Biochemical Pharmacology·Renate StrohmeierHerbert Kuhl
Aug 21, 2003·The Journal of Pharmacology and Experimental Therapeutics·Nathalie LeducqJean-Marc Herbert
Oct 11, 2003·Biochemical and Biophysical Research Communications·V VinJ M Herbert
Jun 9, 2004·Biochemical Pharmacology·Beatrice ChelliClaudia Martini
Jul 31, 2004·Journal of the American Society of Nephrology : JASN·Oxana R KunduzovaAngelo Parini
Feb 16, 2005·Biochemical Pharmacology·Gregory HansJean-Michel Rigo
Aug 11, 2005·Oncogene·Rosa-Ana Gonzalez-PoloGuido Kroemer
Oct 26, 2005·Cell Death and Differentiation·N ZamzamiG Kroemer
Dec 13, 2005·Pharmacology & Therapeutics·Leo Veenman, Moshe Gavish
Nov 28, 2006·Biochemical Pharmacology·Wenping LiVassilios Papadopoulos
Feb 13, 2007·European Journal of Pharmacology·Jingyuan LiYinming Zeng
Apr 5, 2007·Nature Protocols·Carlo Riccardi, Ildo Nicoletti
Dec 24, 2008·Anesthesiology·Hee Kyoung JooByeong Hwa Jeon
Citations
Apr 5, 2013·Cardiovascular Research·Stéphanie ParadisDidier Morin
Aug 30, 2014·Expert Opinion on Investigational Drugs·Ernest AdeghateHuba Kalász
May 24, 2012·FEBS Letters·Hee Kyoung JooByeong Hwa Jeon
Jan 3, 2012·Biochemical and Biophysical Research Communications·Camila Bento de LimaSandra Helena Poliselli Farsky
Aug 31, 2014·Bioorganic & Medicinal Chemistry Letters·Yiu-Yin CheungH Charles Manning